



5151 CORPORATE WAY
JUPITER, FL 33458-3101
(866)720-8386

Client: **RUPA HEALTH, 8011** 25349

DO NOT SHIP TO THIS ADDR

1750 Elm Street Floor 12

MANCHESTER, NH 03104

Phys: [REDACTED] [REDACTED]

Patient: [REDACTED], **ANTHONY**

Phone: [REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

Acc# [REDACTED]

Coll. Date: 06/26/25

[REDACTED]

[REDACTED]

Chart# [REDACTED]

Coll. Time: 07:43 AM

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Report Status: **FINAL**

Test Name	Results	Reference Range	Units
*****OUT OF RANGE SUMMARY*****			
Creatinine	1.28 H	reported: 06/27/25 06:08 0.76 - 1.27	mg/dL *1
LDL Chol Calc (NIH)	103 H	reported: 06/27/25 06:08 0 - 99	mg/dL *1
Estradiol	6.6 L	reported: 06/27/25 06:08 7.6 - 42.6	pg/mL *1
	Roche ECLIA methodology		
Testosterone	>1500 H	reported: 06/27/25 06:08 264 - 916	ng/dL *1
	Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.		
Dihydrotestosterone	16 L	reported: 07/04/25 06:08 ng/dL	*2
	This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Reference Range: Adult Male: 30 - 85		

CBC With Differential/Platelet		reported: 06/27/25 06:08	
WBC	5.3	3.4 - 10.8	x10E3/uL *1
RBC	5.26	4.14 - 5.80	x10E6/uL *1
Hemoglobin	16.4	13.0 - 17.7	g/dL *1
Hematocrit	50.6	37.5 - 51.0	% *1
MCV	96	79 - 97	fL *1
MCH	31.2	26.6 - 33.0	pg *1
MCHC	32.4	31.5 - 35.7	g/dL *1
RDW	12.3	11.6 - 15.4	% *1
Platelets	266	150 - 450	x10E3/uL *1
Neutrophils	47	Not Estab.	% *1
Lymphs	38	Not Estab.	% *1
Monocytes	11	Not Estab.	% *1
Eos	3	Not Estab.	% *1
Basos	1	Not Estab.	% *1
Neutrophils (Absolute)	2.5	1.4 - 7.0	x10E3/uL *1

(Continued on Next Page)


Report Status: FINAL

Test Name	Results	Reference Range	Units
***** (Continued)			
Triiodothyronine (T3), Free	3.1	2.0 - 4.4	pg/mL *I
T4,Free(Direct)	1.14	0.82 - 1.77	ng/dL *I
Vitamin B12	722	232 - 1245	pg/mL *I
Estradiol	6.6 L	7.6 - 42.6	pg/mL *I
	Roche ECLIA methodology		
DHEA-Sulfate	212.0	102.6 - 416.3	ug/dL *I
		reported: 06/27/25 06:08	
Testosterone Free, Profile I			
Testosterone	>1500 H	264 - 916	ng/dL *I
	Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.		
Sex Horm Binding Glob, Serum	55.4	16.5 - 55.9	nmol/L *I
Testost., Free, Calc			pg/mL *I
	Unable to calculate result since non-numeric result obtained for component test.		
		reported: 06/27/25 06:08	
PSA Total+% Free			
Prostate Specific Ag	0.9	0.0 - 4.0	ng/mL *I
	Roche ECLIA methodology.		
	According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.		
PSA, Free	0.26	N/A	ng/mL *I
	Roche ECLIA methodology.		
% Free PSA	28.9		% *I
	The table below lists the probability of prostate cancer for men with non-suspicious DRE results and total PSA between 4 and 10 ng/mL, by patient age (Catalona et al, JAMA 1998, (Continued on Next Page)		

<div style="background-color: black; width: 100%; height: 100%;"></div>	<div style="background-color: black; width: 100%; height: 100%;"></div>
<div style="background-color: black; width: 100%; height: 100%;"></div>	<div style="background-color: black; width: 100%; height: 100%;"></div>
<div style="background-color: black; width: 100%; height: 100%;"></div>	<div style="background-color: black; width: 100%; height: 100%;"></div>

Report Status: FINAL

Test Name	Results	Reference Range	Units
***** (Continued)			
	279:1542) .		
	% Free PSA	50-64 yr	65-75 yr
	0.00-10.00%	56%	55%
	10.01-15.00%	24%	35%
	15.01-20.00%	17%	23%
	20.01-25.00%	10%	20%
	>25.00%	5%	9%
	Please note: Catalona et al did not make specific recommendations regarding the use of percent free PSA for any other population of men.		
Hemoglobin Alc	4.9	reported: 06/27/25 06:08 4.8 - 5.6	% *1
	Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0		
Homocyst(e)ine	10.8	reported: 06/27/25 06:08 0.0 - 14.5	umol/L *1
Dihydrotestosterone	16 L	reported: 07/04/25 06:08 ng/dL	*2
	This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Reference Range: Adult Male: 30 - 85		
Thyroid Antibodies		reported: 06/27/25 15:08	
Thyroid Peroxidase (TPO) Ab	12	0 - 34	IU/mL *1
Thyroglobulin Antibody	<1.0	0.0 - 0.9	IU/mL *1
	Thyroglobulin Antibody measured by Beckman Coulter Methodology		
	It should be noted that the presence of thyroglobulin antibodies may not be pathogenic nor diagnostic, especially at very low levels. The assay manufacturer has found that four percent of individuals without evidence of thyroid disease or autoimmunity will have positive TgAb levels up to 4 IU/mL.		
Vitamin D, 25-Hydroxy	44.3	reported: 06/27/25 06:08 30.0 - 100.0	ng/mL *1
	Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a (Continued on Next Page)		



Report Status: FINAL

COMMENTSEasting.

END OF REPORT

**3) Unless otherwise noted, Tests Performed at :
Labcorp Burlington, 1447 York Court, Burlington, NC 272153361
Director : Sanjai Nagendra, MD 8007624344*